99 studies found for:    "spinocerebellar ataxia type 3" OR "Spinocerebellar Ataxias"
Show Display Options
Rank Status Study
21 Recruiting Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia
Interventions: Behavioral: Error-reduction;   Behavioral: International Cooperative Ataxia Rating Scale;   Behavioral: Scale for the Assessment and Rating of Ataxia;   Behavioral: Beck Depression Inventory, 2nd Ed;   Behavioral: Stroop;   Behavioral: Purdue Pegboard;   Behavioral: Brief Test of Attention;   Behavioral: 6-minute Walk;   Behavioral: Hand Grip Dynamometer;   Behavioral: Montreal Cognitive Assessment;   Behavioral: Physical Performance Function;   Behavioral: Biomechanical Assessments of Dysmetria;   Behavioral: Neurophysiological assessment of brain activity;   Behavioral: Biomechanical gait analysis
22 Completed A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
23 Completed An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
24 Completed A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose;   Drug: Placebo
25 Completed A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373, High dose;   Drug: KPS-0373, Low dose
26 Completed The Effect of Whole Body Vibration Training on Neuromuscular Property in Individuals With Ataxia
Condition: Spinocerebellar Ataxia
Intervention: Other: Whole body vibration training
27 Completed A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Interventions: Drug: KPS-0373;   Drug: Placebo
28 Completed Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: Spinocerebellar Degeneration
Intervention: Drug: KPS-0373
29 Recruiting Efficacy and Safety Study of Mesenchymal Stem Cells (Stemchymal®) in Polyglutamine Spinocerebellar Ataxia
Condition: Cerebellar Ataxia
Interventions: Biological: Stemchymal®;   Procedure: Excipients
30 Recruiting The EUROSCA Natural History Study
Condition: Spinocerebellar Ataxia
Intervention:
31 Completed Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
Conditions: Spinocerebellar Ataxia - All Sub-types;   Friedreich's Ataxia
Intervention: Other: Ataxia rating scale
32 Completed Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)
Condition: Hereditary Ataxia
Intervention:
33 Completed The Investigation of the Pre-movement Facilitation of Agonist-antagonist Muscles and the Effect of the Feedforward Rehabilitation in Individuals With Hypermetria
Condition: Spinocerebellar Atrophy (SCA)
Intervention: Other: Temporal electrical stimulation
34 Completed High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
Condition: Spinocerebellar Degenerations
Intervention: Drug: high-dose intravenous immunoglobulin (IVIG)
35 Completed A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Condition: SCD
Interventions: Drug: KPS-0373;   Drug: Placebo
36 Completed Efficacy of Riluzole in Hereditary Cerebellar Ataxia
Condition: Cerebellar Ataxia
Interventions: Drug: riluzole;   Drug: Placebo comparator
37 Completed Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias
Conditions: Congenital Cerebellar Ataxias;   Early-onset Cerebellar Ataxias
Intervention: Genetic: blood sample
38 Completed Coenzyme Q10 in Adult-Onset Ataxia
Condition: Sporadic Ataxia
Interventions: Drug: Placebo (sugar pill);   Drug: Coenzyme Q10
39 Not yet recruiting EDS in Ataxia Telangiectasia Patients
Conditions: Nervous System Disease;   Genetic Disease;   Rare Disease
Interventions: Drug: EDS-EP dose range of ~5-10 mg DSP/infusion;   Drug: EDS-EP dose range of ~14-22 mg DSP/infusion;   Drug: Placebo
40 Not yet recruiting Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone
Condition: Ataxia-Telangiectasia
Interventions: Drug: Metformin;   Drug: Pioglitazone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years